

**Table 1. Examples of plain polysaccharide vaccines and polysaccharide-protein conjugate vaccines**

Vaccines		Manufacturer	Bacterial target	Capsular polysaccharides (CPS) included in vaccine	Carrier Protein
PLAIN POLYSACCHARID E VACCINES	PNEUMOVAX®23 PNEUMO 23® PNEUMUNE®	Merck Aventis Pasteur Wyeth-Lederle	<i>Streptococcus pneumoniae</i>	CPS from 23 pneumococcal serotypes: 25µg/dose of each type 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F <sup>a</sup>	
	HIB (not in use anymore)		Haemophilus influenzae type	CPS from Haemophilus influenzae type b (polyribosyl-ribitol phosphate or PRP)	
POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES	PREVNAR® (7-valent)	Wyeth-Lederle	<i>Streptococcus pneumoniae</i>	CPS from 7 pneumococcal serotypes conjugated to a mutant diphtheria toxin: 2µg/dose of each type 4, 9V, 14, 18C, 19F, 23F serotypes and 4µg/dose of type 6B	Diphtheria CRM <sub>197</sub> protein
	In clinical trial (9-valent)	Wyeth-Lederle	<i>Streptococcus pneumoniae</i>	CPS from 9 pneumococcal serotypes conjugated to a mutant diphtheria toxin: 2 µg/dose of type 1, 4, 5, 9V, 14, 19F, 23F; 2µg/dose of type 18C and 4µg of type 6B	Diphtheria CRM <sub>197</sub> protein
	In clinical trial (11-valent)	Aventis Pasteur	<i>Streptococcus pneumoniae</i>	CPS from 11 pneumococcal serotypes conjugated to diphtheria toxoid (3, 6B, 14, 18C) or tetanus toxoid (1, 4, 5, 7F, 9V, 19F, 23F): 1µg/dose of type 1, 4, 5, 7F, 9V, 19F, 23F, 3µ/dose of type 3, 14, 18C and 10µg/dose of type 6B	Tetanus and diphtheria toxoids
	Act-HIB®	Aventis Pasteur	Haemophilus influenzae type b	CPS from Haemophilus influenzae type b (10µg) conjugated to tetanus toxoid	Tetanus toxoid
	Pedvax HIB®	Merck	Haemophilus influenzae type b	CPS from Haemophilus influenzae type b (15µg) conjugated to meningococcal outer membrane protein	meningococcal outer membrane protein

<sup>a</sup> Danish Nomenclature